http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 16:31:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+17++Filed+by%3A+MAHONEY+DAVID+L/26666588.html si-local-file:///var/storage/secattach/20260618/26666588.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+17++Filed+by%3A+MAHONEY+DAVID+L/26666588.html Thu, 18 Jun 2026 16:31:00 -0400 CORT O.00646884 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+17++Filed+by%3A+MAHONEY+DAVID+L/26666588.html si-local-file:///var/storage/secattach/20260618/26666588.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+17++Filed+by%3A+MAHONEY+DAVID+L/26666588.html Thu, 18 Jun 2026 16:31:00 -0400 CORT O.00646884 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+16++Filed+by%3A+WILSON+JAMES+N/26666603.html si-local-file:///var/storage/secattach/20260618/26666603.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+16++Filed+by%3A+WILSON+JAMES+N/26666603.html Thu, 18 Jun 2026 16:31:00 -0400 CORT O.00646884 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+16++Filed+by%3A+WILSON+JAMES+N/26666603.html si-local-file:///var/storage/secattach/20260618/26666603.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+16++Filed+by%3A+WILSON+JAMES+N/26666603.html Thu, 18 Jun 2026 16:31:00 -0400 CORT O.00646884 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+17/26660515.html si-local-file:///var/storage/secattach/20260617/26660515.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+17/26660515.html Wed, 17 Jun 2026 16:37:00 -0400 CORT O.00646884 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+17/26660515.html si-local-file:///var/storage/secattach/20260617/26660515.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+17/26660515.html Wed, 17 Jun 2026 16:37:00 -0400 CORT O.00646884 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+15++Filed+by%3A+Mokari+Atabak/26660384.html si-local-file:///var/storage/secattach/20260617/26660384.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+15++Filed+by%3A+Mokari+Atabak/26660384.html Wed, 17 Jun 2026 16:30:00 -0400 CORT O.00646884 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+15++Filed+by%3A+Mokari+Atabak/26660384.html si-local-file:///var/storage/secattach/20260617/26660384.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CORCEPT+THERAPEUTICS++++++For%3A+Jun+15++Filed+by%3A+Mokari+Atabak/26660384.html Wed, 17 Jun 2026 16:30:00 -0400 CORT O.00646884 http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html <p>Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for Cushing's syndrome, according to a company statement.</p> <p>The resubmission includes additional analyses of data from the original NDA, as requested by the FDA. Corcept expects the resubmission to receive a six-month review.</p> <p>The filing is supported by data from the pivotal GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, a long-term extension study, and earlier-stage development data. Corcept said the data indicate relacorilant provides improvements in the signs and symptoms of Cushing's syndrome without some of http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html Wed, 17 Jun 2026 16:28:12 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html <p>Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for Cushing's syndrome, according to a company statement.</p> <p>The resubmission includes additional analyses of data from the original NDA, as requested by the FDA. Corcept expects the resubmission to receive a six-month review.</p> <p>The filing is supported by data from the pivotal GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, a long-term extension study, and earlier-stage development data. Corcept said the data indicate relacorilant provides improvements in the signs and symptoms of Cushing's syndrome without some of http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html Wed, 17 Jun 2026 16:28:12 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html <p>Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for Cushing's syndrome, according to a company statement.</p> <p>The resubmission includes additional analyses of data from the original NDA, as requested by the FDA. Corcept expects the resubmission to receive a six-month review.</p> <p>The filing is supported by data from the pivotal GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, a long-term extension study, and earlier-stage development data. Corcept said the data indicate relacorilant provides improvements in the signs and symptoms of Cushing's syndrome without some of http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html Wed, 17 Jun 2026 16:28:12 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html <p>Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for Cushing's syndrome, according to a company statement.</p> <p>The resubmission includes additional analyses of data from the original NDA, as requested by the FDA. Corcept expects the resubmission to receive a six-month review.</p> <p>The filing is supported by data from the pivotal GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, a long-term extension study, and earlier-stage development data. Corcept said the data indicate relacorilant provides improvements in the signs and symptoms of Cushing's syndrome without some of http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html Wed, 17 Jun 2026 16:28:12 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html <p>Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for Cushing's syndrome, according to a company statement.</p> <p>The resubmission includes additional analyses of data from the original NDA, as requested by the FDA. Corcept expects the resubmission to receive a six-month review.</p> <p>The filing is supported by data from the pivotal GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, a long-term extension study, and earlier-stage development data. Corcept said the data indicate relacorilant provides improvements in the signs and symptoms of Cushing's syndrome without some of http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html Wed, 17 Jun 2026 16:28:12 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html <p>Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for Cushing's syndrome, according to a company statement.</p> <p>The resubmission includes additional analyses of data from the original NDA, as requested by the FDA. Corcept expects the resubmission to receive a six-month review.</p> <p>The filing is supported by data from the pivotal GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, a long-term extension study, and earlier-stage development data. Corcept said the data indicate relacorilant provides improvements in the signs and symptoms of Cushing's syndrome without some of http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html Wed, 17 Jun 2026 16:28:12 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html <p>Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for Cushing's syndrome, according to a company statement.</p> <p>The resubmission includes additional analyses of data from the original NDA, as requested by the FDA. Corcept expects the resubmission to receive a six-month review.</p> <p>The filing is supported by data from the pivotal GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, a long-term extension study, and earlier-stage development data. Corcept said the data indicate relacorilant provides improvements in the signs and symptoms of Cushing's syndrome without some of http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html Wed, 17 Jun 2026 16:28:12 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html <p>Corcept Therapeutics (NASDAQ: CORT) has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for Cushing's syndrome, according to a company statement.</p> <p>The resubmission includes additional analyses of data from the original NDA, as requested by the FDA. Corcept expects the resubmission to receive a six-month review.</p> <p>The filing is supported by data from the pivotal GRACE trial, the double-blind, placebo-controlled Phase III GRADIENT trial, a long-term extension study, and earlier-stage development data. Corcept said the data indicate relacorilant provides improvements in the signs and symptoms of Cushing's syndrome without some of http://www.streetinsider.com/FDA/Corcept+resubmits+NDA+for+relacorilant+to+treat+Cushing%27s+syndrome/26660312.html Wed, 17 Jun 2026 16:28:12 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html <p> REDWOOD CITY, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.</p><p class="bwalignl">As requested by the FDA, the resubmission includes additional analyses of data included in the original NDA submission. Corcept expects the resubmission to receive a six-month review.</p><p class="bwalignl">“We are pleased to http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html Wed, 17 Jun 2026 16:28:00 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html <p> REDWOOD CITY, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.</p><p class="bwalignl">As requested by the FDA, the resubmission includes additional analyses of data included in the original NDA submission. Corcept expects the resubmission to receive a six-month review.</p><p class="bwalignl">“We are pleased to http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html Wed, 17 Jun 2026 16:28:00 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html <p> REDWOOD CITY, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.</p><p class="bwalignl">As requested by the FDA, the resubmission includes additional analyses of data included in the original NDA submission. Corcept expects the resubmission to receive a six-month review.</p><p class="bwalignl">“We are pleased to http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html Wed, 17 Jun 2026 16:28:00 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html <p> REDWOOD CITY, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.</p><p class="bwalignl">As requested by the FDA, the resubmission includes additional analyses of data included in the original NDA submission. Corcept expects the resubmission to receive a six-month review.</p><p class="bwalignl">“We are pleased to http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html Wed, 17 Jun 2026 16:28:00 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html <p> REDWOOD CITY, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.</p><p class="bwalignl">As requested by the FDA, the resubmission includes additional analyses of data included in the original NDA submission. Corcept expects the resubmission to receive a six-month review.</p><p class="bwalignl">“We are pleased to http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html Wed, 17 Jun 2026 16:28:00 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html <p> REDWOOD CITY, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.</p><p class="bwalignl">As requested by the FDA, the resubmission includes additional analyses of data included in the original NDA submission. Corcept expects the resubmission to receive a six-month review.</p><p class="bwalignl">“We are pleased to http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html Wed, 17 Jun 2026 16:28:00 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html <p> REDWOOD CITY, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.</p><p class="bwalignl">As requested by the FDA, the resubmission includes additional analyses of data included in the original NDA submission. Corcept expects the resubmission to receive a six-month review.</p><p class="bwalignl">“We are pleased to http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html Wed, 17 Jun 2026 16:28:00 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html <p> REDWOOD CITY, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.</p><p class="bwalignl">As requested by the FDA, the resubmission includes additional analyses of data included in the original NDA submission. Corcept expects the resubmission to receive a six-month review.</p><p class="bwalignl">“We are pleased to http://www.streetinsider.com/Press+Releases/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html Wed, 17 Jun 2026 16:28:00 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661 http://www.streetinsider.com/Business+Wire/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html <p> REDWOOD CITY, Calif.--(BUSINESS WIRE)--</p> <p class="bwalignl">Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.</p><p class="bwalignl">As requested by the FDA, the resubmission includes additional analyses of data included in the original NDA submission. Corcept expects the resubmission to receive a six-month review.</p><p class="bwalignl">“We are pleased to http://www.streetinsider.com/Business+Wire/Corcept+Resubmits+New+Drug+Application+for+Relacorilant+as+a+Treatment+for+Patients+with+Cushing%E2%80%99s+Syndrome/26660308.html Wed, 17 Jun 2026 16:28:00 -0400 A.06822034 A.31066700 A.60012004 CORT O.00646884 O.01304637 O.20026344 O.22422661